benefits of glp-1 agonists The expanding medicines: Cell Reports Medicine GLP-1 receptor agonists and cardiovascular
Description
The United States is anticipated to grow at a CAGR of 5.2% from 2026 to 2036, supported by increasing diabetic prevalence, ongoing research in diabetes treatment, and widespread adoption of GLP-1 receptor agonists in managing type 2 diabetes
FGF, Fibroblast growth factor
S.SharmaA
This guide will break down everything you need to know about these drugs, their differences, how they work, and their potential side effects
[DOI] [PubMed] [Google Scholar] 23.Duggan E.W., Carlson K., Umpierrez G.E
